Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LMRI vs KMTS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KMTS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–1 Matrix Metrics)

KMTS Overall Winner 6-Pillar Tally: LMRI 0 – 4 KMTS (2 Tie) Matrix Metrics: LMRI 1 – 7 KMTS

As of Nov 20, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LMRI carries a Unified Composite Score of 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin), whereas KMTS carries 46.9/100 (HOLD) at $25.10 (N/M Forward P/E, -134.5% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LMRI vs KMTS
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73
KMTS NASDAQ Head-to-Head Winner
Kestra Medical Technologies, Ltd. Common Stock
Surgical & Medical Instruments & Apparatus
$25.10
-5.75% 1D
Market Cap $1.6B
TTM Revenue $107M
Forward P/E N/M
Beta / 30D Vol 1.74β · 63% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 37.0 Fund 43.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.6 · SMA20: $29.05 · SMA50: $27.68

6-Pillar Scorecard Institutional Category Breakdown (LMRI 0 – 4 KMTS)

Columns: Metric · LMRI · KMTS
1. Valuation Multiples KMTS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 14.4x
2. Growth & Scale KMTS
Revenue Growth (YoY) N/A +59.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $107M
Market Cap N/A $1.6B
3. Profitability & Quality KMTS
Gross Margin N/A 53.9%
Operating Margin N/A -134.5%
Net Profit Margin N/A -140.4%
Return on Equity (ROE) N/A -73.7%
4. Balance Sheet & Cash Flow KMTS
Cash Generation (TTM) N/A -$117M
Cash Flow Margin N/A -109.7%
Net Cash / Leverage N/A ROE $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LMRI (1) vs KMTS (7)
Institutional Metric LMRI KMTS Criterion Row Edge
Market Capitalization
Scale
N/A $1.6B Larger Scale KMTS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +59.9% Higher Growth KMTS
Operating Margin (TTM)
Profitability
N/A -134.5% Higher Margin KMTS
Net Profit Margin
Profitability
N/A -140.4% Higher Margin KMTS
Return on Equity (ROE)
Capital Efficiency
N/A -73.7% Higher ROE KMTS
52-Week Range Position
Momentum
60% ($6–$19) 53% ($17–$32) Stronger Trend LMRI
Beta / 30D Volatility
Risk Regime
1.22β · 85% Vol 1.74β · 63% Vol Lower Realized Risk KMTS
Unified Institutional Score
Composite Signal
32.1 / 100 (SELL) 46.9 / 100 (HOLD) Higher Composite KMTS
Trailing 12M Revenue (USD)
Operating Scale
N/A $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 53.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$117M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +42.32 pp
LMRI: +30.95% · KMTS: -11.37%
3M Horizon LMRI +27.07 pp
LMRI: +20.34% · KMTS: -6.73%
6M Horizon LMRI +62.26 pp
LMRI: +78.25% · KMTS: +15.99%
1Y Horizon KMTS +23.76 pp
LMRI: -23.0% · KMTS: +0.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LMRI vs KMTS. Trailing 12-month operating profitability (LMRI N/A vs KMTS -134.5%) and valuation multiples (LMRI N/M vs KMTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
KMTS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$107M
Gross Margin53.9%
Op. Margin-134.5%
ROE / Fwd P/E-73.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KMTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KMTS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.6B market capitalization and -134.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LMRI vs KMTS Key Questions & Quantitative Answers

As of Nov 20, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LMRI carries a Unified Composite Score of 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin), whereas KMTS carries 46.9/100 (HOLD) at $25.10 (N/M Forward P/E, -134.5% operating margin). Technically, LMRI sits in a Markup phase (RSI 62.5, UNCLASSIFIED options structure) and KMTS sits in a Neutral phase (RSI 37.6, UNCLASSIFIED options structure).

KMTS leads the Growth & Scale pillar: LMRI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with KMTS at +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin). On trailing 12-month operating scale, LMRI generates N/A in USD-normalized revenue versus $107M for KMTS. In operating R&D and SG&A reinvestment, LMRI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KMTS.

KMTS screens cheaper on headline valuation multiples. LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.4x EV/Revenue (-109.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LMRI (N/A ROE) versus KMTS (-73.7% ROE) capital efficiency.

In options market volatility and institutional positioning, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk). By comparison, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.